EW
Edwards Lifesciences Corporation
$81.34
+$0.11(+0.14%)
66
Overall
70
Value
63
Tech
--
Quality
Market Cap
$47.71B
Volume
2.74M
52W Range
$64.01 - $83.00
Target Price
$87.31
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.5B | $3.0B | $3.4B | $3.7B | $4.3B | $4.4B | $5.2B | $5.4B | $5.0B | $5.4B | ||
| Total Revenue | $2.5B | $3.0B | $3.4B | $3.7B | $4.3B | $4.4B | $5.2B | $5.4B | $5.0B | $5.4B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $617.2M | $797.4M | $875.3M | $939.4M | $1.1B | $1.1B | $1.2B | $1.1B | $978.4M | $1.1B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.9B | $2.2B | $2.6B | $2.8B | $3.2B | $3.3B | $4.0B | $4.3B | $4.0B | $4.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $1.2B | $1.3B | $1.5B | $1.7B | $2.0B | $2.0B | $2.4B | $2.5B | $2.5B | $2.8B | ||
| Research & Development | $383.1M | $442.2M | $552.6M | $622.2M | $752.7M | $760.7M | $903.1M | $945.2M | $962.9M | $1.1B | ||
| Research Expense | $383.1M | $442.2M | $552.6M | $622.2M | -- | -- | $903.1M | $945.2M | $962.9M | $1.1B | ||
| Selling, General & Administrative | $850.7M | $904.7M | $990.8M | $1.1B | $1.2B | $1.2B | $1.5B | $1.6B | $1.6B | $1.8B | ||
| General & Administrative Expenses | $850.7M | $904.7M | $990.8M | $1.1B | -- | -- | $1.5B | $1.6B | $1.6B | $1.8B | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | $-18.9M | -- | -- | -- | ||
| Depreciation & Amortization | $58.7M | $63.6M | $74.1M | $74.9M | -- | -- | $127.0M | $133.9M | $119.9M | $137.6M | ||
| Depreciation & Amortization | $58.7M | $63.6M | $74.1M | $74.9M | -- | -- | $127.0M | -- | -- | -- | ||
| Amortization | $628.3M | $626.1M | $1.1B | $1.1B | -- | -- | $1.2B | $1.2B | $1.1B | $1.8B | ||
| Other Operating Expenses | $-29.6M | $-29.0M | $700.0K | $-37.8M | -- | -- | $-82.1M | -- | -- | $-300.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $642.7M | $819.4M | $1.1B | $748.2M | $1.2B | $1.3B | $1.7B | $1.7B | $1.3B | $1.4B | ||
| EBITDA | $705.4M | $828.3M | $1.1B | $838.6M | $1.3B | $1.0B | $1.9B | $2.0B | $1.6B | $1.7B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $17.2M | $19.2M | $23.2M | $29.9M | $20.7M | $15.8M | $18.4M | $19.2M | $17.6M | $19.8M | ||
| Intinc | $7.9M | $10.8M | $20.3M | $32.0M | $32.2M | $23.4M | $17.4M | $35.5M | $67.2M | $120.3M | ||
| Net Non-Operating Interest Income/Expense | $-9.3M | $-8.4M | $-2.9M | $2.1M | $11.5M | $7.6M | $-1.0M | $16.3M | $49.6M | $100.5M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $6.4M | $12.9M | -- | -- | -- | -- | ||
| Other Income/Expense | $4.0M | $6.0M | $-8.5M | $-9.7M | $83.7M | $407.5M | $-136.8M | $-39.2M | $-40.1M | $-68.9M | ||
| Other Special Charges | $-4.0M | $-4.9M | $-1.4M | $4.0M | $8.2M | $11.5M | $12.7M | $2.6M | $13.9M | $68.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $61.0M | ||
| Special Income Charges | $-7.0M | $-67.1M | $63.6M | $-330.2M | $-91.9M | $-419.0M | $-20.6M | $-60.7M | $-203.5M | $-101.4M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $-40.6M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $639.6M | $757.1M | $1.0B | $761.2M | $1.2B | $932.5M | $1.7B | $1.8B | $1.4B | $1.6B | ||
| Pre-Tax Income | $622.4M | $737.9M | $1.0B | $761.4M | $1.2B | $916.7M | $1.7B | $1.8B | $1.4B | $1.5B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $127.5M | $168.4M | $451.3M | $39.2M | $119.6M | $93.3M | $198.9M | $245.5M | $152.4M | $152.1M | ||
| NET INCOME | ||||||||||||
| Net Income | $494.9M | $569.5M | $583.6M | $722.2M | $1.0B | $823.4M | $1.5B | $1.5B | $1.4B | $4.2B | ||
| Net Income (Continuing Operations) | $494.9M | $569.5M | $583.6M | $722.2M | $1.0B | $823.4M | $1.5B | $1.5B | $1.2B | $1.4B | ||
| Net Income (Discontinued Operations) | $494.9M | $569.5M | $583.6M | $722.2M | $1.0B | $823.4M | $1.5B | $1.5B | $1.4B | $4.2B | ||
| Net Income (Common Stockholders) | $494.9M | $569.5M | $583.6M | $722.2M | $1.0B | $823.4M | $1.5B | $1.5B | $1.4B | $4.2B | ||
| Normalized Income | -- | -- | -- | -- | $1.0B | $1.1B | -- | -- | -- | -- | ||
| TOTALS | ||||||||||||
| Total Expenses | $1.9B | $2.1B | $2.4B | $2.7B | $3.1B | $3.1B | $3.6B | $3.6B | $3.5B | $4.0B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $215.5M | $213.0M | $210.9M | $209.2M | $624.9M | $622.6M | $623.3M | $619.0M | $606.7M | $597.7M | ||
| Average Shares Outstanding (Diluted) | $220.3M | $217.8M | $215.9M | $213.6M | $636.6M | $631.9M | $631.2M | $624.2M | $609.4M | $599.3M | ||
| Shares Outstanding | $643.8M | $637.5M | $630.1M | $623.3M | $627.4M | $624.5M | $623.2M | $608.3M | $601.3M | $587.9M | ||
| Basic EPS | $2.3 | $2.67 | $2.77 | $3.45 | $1.68 | $1.32 | $2.41 | $2.46 | $2.31 | $6.98 | ||
| Basic EPS (Continuing Operations) | $2.3 | $2.67 | $2.77 | $3.45 | $1.68 | $1.32 | $2.41 | $2.46 | $2.31 | $2.34 | ||
| Diluted EPS | $2.25 | $2.61 | $2.7 | $3.38 | $1.64 | $1.3 | $2.38 | $2.44 | $2.3 | $6.97 | ||
| Diluted EPS (Continuing Operations) | $2.25 | $2.61 | $2.7 | $3.38 | $1.64 | $1.3 | $2.38 | $2.44 | $2.3 | $2.34 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $4.64 | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $4.63 | ||
| Insurance And Claims | -- | -- | -- | -- | -- | -- | -- | $-3.8M | -- | -- | ||
| Interest Expense Operating | -- | -- | $-19.9M | $-30.1M | -- | -- | $-20.2M | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | -- | -- | -- | -- | $3.0M | $4.9M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | $179.4M | $2.8B | ||
| Non Recurring Operation Expense | $7.0M | $67.1M | $-63.6M | $330.2M | -- | -- | $20.6M | $60.7M | $203.5M | $40.4M | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | -- | -- | -- | $179.4M | $2.8B | ||
| Other Gand A | $850.7M | $904.7M | $990.8M | $1.1B | -- | -- | $1.5B | $1.6B | $1.6B | $1.8B | ||
| Rent And Landing Fees | $22.5M | $22.9M | $27.3M | $27.0M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $-98.0M | $-405.4M | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | -- | $61.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EW | $81.34 | +0.1% | 2.74M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Edwards Lifesciences Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW